IL-PROJECT44
17.10.2018 09:02:30 CEST | Business Wire | Press release
project44 (p44) and Gatehouse Logistics jointly announced today that they have entered into an exclusive, multinational agreement which will provide secure and authorized access to the largest visibility network across North America and Europe. Ultimately, accelerating the ability for both technology providers to deliver visibility solutions across multiple transportation modes and geographies.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181017005211/en/
End-to-end supply chain visibility is critical for complex global organizations looking to monitor global operations, increase efficiencies and improve the overall customer experience. This first of its kind multinational partnership provides visibility into key transportation processes, ensuring global organizations can accurately see and proactively respond to all events in their supply chain at the “speed of thought.”
Gatehouse Logistics CEO Jesper Bennike commented that, “project44 and Gatehouse Logistics have been championing the importance of high-fidelity data for years. This collaboration aligns with both company’s core promise to deliver the most comprehensive global visibility engine powered only by secure, high-quality and real-time information.”
Since 1992, Gatehouse Logistics has been leading the way in securely sharing data across the supply chain, bringing with it much-needed visibility of inbound and outbound logistics. ghTrack is a GDPR compliant, neutral and hardware agnostic data sharing service enabling Gatehouse Logistics to build the largest network of telematics systems across Europe. Similarly, project44 has quickly become the leader in North American advanced visibility by building the largest and most inclusive network of capacity providers connected via ELD, telematics, direct API connections, app-less tracking, or smartphone applications.
With this partnership, customers of project44 and Gatehouse Logistics now have immediate and actionable access to a network of 175,000 multimodal carriers - comprised of 90,000 capacity providers in North America and 85,000 in Europe. Implementation processes have also been expedited to ensure fast and frictionless onboarding for all customers and rapid time-to-value.
“Visibility is the number one supply chain initiative. We’ve seen a record number of North American and European companies investing in real-time visibility platforms to be used either stand-alone or with a TMS, CRM, WMS or ERP,” said project44 founder and CEO Jett McCandless. “This partnership accelerates the speed at which manufacturers, retailers, ecommerce providers, distributors, freight forwarders, and 3PLs can successfully realize the benefits of end-to-end visibility by working with a single visibility provider for all shipments regardless of geographic location.”
To learn more about this exclusive partnership or schedule a demo, visit https://get.project44.com/ghl-partnership/ . Executive leaders from project44 and Gatehouse Logistics will be attending the 35th International Supply Chain Conference in Berlin (October 17-19, 2018) hosted by BVL. Editors attending the BVL Conference are invited to a reception in Gartenlounge II at 14:00 on October 17 for an exclusive briefing.
About project44:
project44 is the world’s leading advanced visibility platform for shippers and third-party logistics firms. project44 connects, automates and provides visibility into key transportation processes to accelerate insights and shorten the time it takes to turn those insights into actions. Leveraging the power of the project44 cloud-based platform, organizations are able to increase operational efficiencies, reduce costs, improve shipping performance, and deliver an exceptional Amazon-like experience to their customers. Connected to over 175,000 carriers worldwide and having comprehensive coverage for all ELD and telematics devices on the market, project44 supports all transportation modes and shipping types, including Parcel, Final-Mile, Less-than-Truckload, Volume Less-than-Truckload, Truckload, Rail, Intermodal, and Ocean. To learn more, visit www.project44.com .
About GateHouse Logistics A/S:
GateHouse Logistics is the brand owner of ghTrack, a completely neutral and independent cloud-based data sharing service that is leading the way business-critical data is securely shared across the entire supply chain. It is also the perfect foundation for emerging smart industries including IoT developments. ghTrack brings long-wanted, real-time end-to-end visibility to all stakeholders in the supply chain. It aggregates position and sensor data from all modes of transportation and presents them as one unified and logical data stream for simple integration into any business system. ghTrack is Europe’s most widely used, secure and GDPR compliant data sharing service. Visit www.ghTrack.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20181017005211/en/
Contact:
North American Media Contact: project44 Ally Lynch, VP Marketing Phone: 1-312-300-4899 Email: ally@project44.com or European Media Contact: GateHouse Logistics Mette Lilkær, Strategic Sales & Marketing Manager Landline: + 45 7020 1909. Mobile + 45 2920 2383 Email: mdl@gatehouse.dk
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom